April 12, 2022
RegMed Investors’ (RMi) closing bell: snap, crackle and no pop as liquidity drains from the sector as indexes dives again
April 8, 2022
RegMed Investors’ (RMi) closing bell: it will pay to be early in buying newest bottoms
April 6, 2022
RegMed Investors’ (RMi) closing bell: uncertainty trips upside momentum
April 5, 2022
RegMed Investors’ (RMi) closing bell: rough ride with news spelling share pricing risk
April 4, 2022
RegMed Investors’ (RMi) closing bell: back on top in a tricky environment for cell and gene therapy sector equities
April 1, 2022
RegMed Investors’ (RMi) closing bell: an uptick for the oversold
March 31, 2022
RegMed Investors’ (RMi) closing bell: struggling for direction with fading optimism as March and Q1 end
March 30, 2022
RegMed Investors’ (RMi) closing bell: the impact of doubts about the strength of a recent market rebound
March 25, 2022
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector got robbed again of share pricing value
March 24, 2022
RegMed Investors’ (RMi) closing bell: upside holding its own while riding the waves of a positive market
March 23, 2022
RegMed Investors’ (RMi) closing bell: after yesterday’s gains, there’s today’s pains – yet again
March 22, 2022
RegMed Investors’ (RMi) closing bell: adjusting expectation, the monkey bars versus the slide
March 21, 2022
RegMed Investors’ (RMi) closing bell: The sector got whacked as the electronics and algorithms ate through any upside
March 21, 2022
RegMed Investors’ (RMi) closing bell: sector highs respond to lessened resistance motivating sentiment
March 21, 2022
RegMed Investors’ (RMi) pre-open: holding onto gains or evacuate from risk
March 17, 2022
RegMed Investors’ (RMi) closing bell: Algorithmic tailwinds are pushing the cell and gene therapy sector upward
March 15, 2022
RegMed Investors’ (RMi) closing bell: it’s about time for the oversold cell and gene therapy sector logjam to come back to appreciation
March 14, 2022
RegMed Investors’ (RMi) closing bell: just when I thought sentiment would rebound and lift the cell and gene therapy sector
March 11, 2022
RegMed Investors’ (RMi) closing bell: escalated depreciation in the cell and gene therapy sector
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors